178 results about "Prolactin" patented technology

The claimed invention describes methods to diagnose or aid in the diagnosis of cancer. The claimed methods are based on the identification of biomarkers which are particularly well suited to discriminate between cancer subjects and healthy subjects. These biomarkers were identified using a unique and novel screening method described herein. The biomarkers identified herein can also be used in the prognosis and monitoring of cancer. The invention comprises the use of leptin, prolactin, OPN and IGF-II for diagnosing, prognosis and monitoring of ovarian cancer.

Disclosed is a breast pump that supports a mother's and infant's breastfeeding needs and facilitates the lifestyle of the mother's choice. The breast milk expression system disclosed allows breastfeeding mothers to obtain milk comfortably, hands-free, conveniently and with discretion. The breast milk expression system disclosed includes at least two contact points which mimic hand-expression as well as infant suckling and effectively stimulate the secretion of oxytocin and prolactin to provide a healthy, safe and efficient breastfeeding session. The system disclosed has a gentle rhythmic massage means and is located a distance from the base of the nipple and massages in all quadrants of the breast. The rhythmic forward pressure is provided by a plurality of opposing pairs of expression bellows that move the milk from the lactiferous sinuses through the nipple pores, bio-mimicking the techniques of hand expression.

A complex is provided for the treatment of neurogenic conditions having the formula:

where R¹ is

M is a metal ion Ca(II), Mg(II), Cu(II) or Ni(II); n is an integer 1 or 2; R is BBB peptide, transferrin, membrane transporter peptide, TAT peptide, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, thyrotropin, an angiotensin, galanin, neuropeptide Y, thyrotropin-releasing hormone, gonadotropnin-releasing hormone, growth hormone-releasing hormone, luteinizing hormone, vasoactive intestinal peptidegluconate, L-lactate, L-leucine, L-tryptophan, and L-glutamate; and R is coupled to M through a carboxylate moiety. Magnesium (II) represents the preferred metal ion as magnesium is known to have neuroprotective effects. The metal ion is in part chelated by a non-steroidal anti-inflammatory drug that does not inhibit platelet activity and includes salicylate and ibuprofenate. The complex also includes a ligand operative in transport across the blood brain barrier. A process for making an inventive complex includes the stoichiometric addition of ligands containing carboxylate groups to a solution of the metal ion. In instances where the metal ion is magnesium (II), a stoichiometric ratio of 1:1:1 is found between the non-steroidal anti-inflammatory ligand:magnesium (II):transporter ligand.

A compound is provided that has the formula

NH₂CH₂CH₂CH₂C(O)N—R   (I)

where R is a moiety capable of crossing the blood brain barrier and is as a free compound serotonin, dopamine blood brain barrier (BBB) peptide, membrane translocating protein, TAT peptides, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, thyrotropin, an angiotensin, galanin, neuropeptide Y, thyrotropin-releasing hormone, gonadotropnin-releasing hormone, growth hormone-releasing hormone, luteinizing hormone, vasoactive intestinal peptidetransferrin, glucosylamnine, amino saccharin, lactylamine, leucine, tryptophan, glutamate and amino cholines.

A compound is provided that has the formula

NH₂CH₂CH₂CHR¹C(O)N—R  (I)

where R¹ is p-chlorophenyl, R is a moiety capable of crossing the blood brain barrier and is as a free compound serotonin, dopamine blood brain barrier (BBB) peptide, membrane translocating protein, TAT peptides, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, thyrotropin, an angiotensin, galanin, neuropeptide Y, thyrotropin-releasing hormone, gonadotropnin-releasing hormone, growth hormone-releasing hormone, luteinizing hormone, vasoactive intestinal peptide transferrin, glucosylamine, amino saccharin, lactylamine, leucine, tryptophan, glutamate and amino cholines.

The present invention provides for a method for stimulating the proliferation of pluripotential stem cells in a mammal comprising administration of pregnancy related compounds more particularly human chorionic gonadotropin, leutenizing hormone or prolactin. The present invention further provides for a method of treatment of tissues or organs experiencing cellular damage, injury or disease.

We have discovered that growth hormones from ternary complexes with their receptors in which site 1 on the hormone first binds to one molecule of receptor and then hormone site 2 then binds to another molecule of receptor, thereby producing a 1:2 complex. We believe this phenomenon is shared by other ligands having similar conformational structure. Assays based on this phenomenon are useful for identifying ligand agonists and antagonists. Sites 1 and 2 are structurally identified to facilitate generation of amino acid sequence variants of ternary complex-forming ligands. Novel variants of growth hormone, prolactin placental lactogen and other related ligands are provided. As a result of our studies with the ternary complex we have determined that selected antibodies to the receptor for these ligands are capable of acting as ligand agonists or antagonists. Novel growth hormones and novel uses for anti-growth hormone receptor antibodies are described.

Intermedin nucleic acid compositions and their encoded polypeptides and variants thereof are provided. Intermedin is a novel ligand for the calcitonin receptor-like receptor. In addition to its use as a therapeutic agent, intermedin sequences are utilized in screening and research methods for the determination of specific analogs, agonists, antagonists and mimetics. Intermedin is highly expressed in the intermediate lobe of the pituitary and is shown to stimulate prolactin release by anterior pituitary cells, and to release of growth hormone. Intermedin treatment leads to blood pressure reduction both in normal and hypertensive subjects, as well as the suppression of gastric emptying activity.

A modified human prolactin molecule wherein the prolactin molecule comprises at least one mutation in a region selected from i) amino acids 41-57, ii) amino acids 94-110, and iii) amino acids 160-173; and wherein the at least one mutation is selected from deletions, replacements, and insertions. The modified prolactins are prolactin antagonists, and can be used in treating cancer, among other conditions.

The present invention relates to a pharmaceutical composition having dopaminergic activity and other related pharmaceutical activities comprising trigonelline or its derivative(s) and 4-hydroxyisoleucine or its derivative(s), optionally along with excipients(s); a process of preparing a pharmaceutical composition comprising trigonelline or its derivative(s) and 4-hydroxyisoleucine or its derivative(s), optionally along with excipients(s), wherein the process comprising steps of: (a) extracting a clear solution containing trigonelline and 4-hydroxyisoleucine from plant source; and (b) optionally precipitating derivative(s) of trigonelline and 4-hydroxyisoleucine from the clear solution and obtaining said composition; and an in-vitro method to increase levels of dopamine or to inhibit prolactin by allowing composition comprising trigonelline or its derivative(s) and 4-hydroxyisoleucine or its derivative(s) to bind to cell receptors.

The invention discloses a prolactin (PRL) time-resolved fluoroimmunoassay method and a kit. The method comprises the following steps: selecting and using a monoclonal antibody against PRL as a coated antibody, and diluting sodium carbonate buffer solution to 1 to 10mu g/ml as coating liquid; preparing a lanthanide ion label against the PRL monoclonal antibody as a labeled antibody; diluting and using the reaction buffer solution according to a ratio of 1 to 20 during experiment; and on a reaction plate of the coated antibody, adding 25mu l of standard substance of PRL or sample to be detected and the diluted labeled antibody into each hole in turn, and carrying out fluorescence detection after hatching. The invention also provides the corresponding kit. The method and the kit have the advantages of high sensitivity, specificity and stability; and the high automated assay system can improve the speed of clinical examination result, greatly reduce human error and increase the reliability of detected result.

The invention discloses a liquid chip kit for diagnosing lung cancer. The kit comprises microballs coated with capturing antibodies, detecting antibodies labeled by biotin, microballs coupled with Halotag Amine (O2) ligand, antigen proteins, streptavidin-phycoerythrin and anti-human immune globulin G labeled by biotin; wherein the capturing antibodies contain at least one component, which is selected from the following capturing antibodies: CRP, Prolactin, CEA, NSE, CK19, Axl and ADAM8; the detecting antibodies contain at least one component, which is selected from the following detecting antibodies: CRP, Prolactin, CEA, NSE, CK19, Axl and ADAM8, and are corresponding to the capturing antibodies; the antigen proteins contain at least one component, which is selected from following components: p62, CTAG, p53 and CAGE. Microballs with different antibodies or antigen proteins have different color codes. The liquid chip kit carries out detections of antigen and autoantibody at the same time, and the precision rate is high.

A novel fusion protein, comprising a receptor-antagonizing domain and an angiogensis inhibiting domain, characterized, for example, by its ability to block apoptosis and/or inhibit endocrine response, is useful in treating cancer. For example, a human prolactin antagonist-endostatin fusion protein combines apoptosis induction and angiogenesis inhibition to combat cancer.

A construct comprising the ectodomain of the Hepatitis C Virus (HCV) E2 sequence and a mammalian expression system therefor is disclosed. The construct comprises a CMV promoter, prolactin signal sequence, the ectodomain of HCV E2 sequence truncated at aa 664, a thrombin cleavage site and a human Fc domain. The method also relates to an expression system for the construct, which is stably expressed in human embryonic kidney cells 293T. Continuous protein expression in a bioreactor allows for 4 mg of purified protein per liter of cell supernatant.

The present invention encompasses novel inhibitors for growth hormone and related hormones, including prolactin, and placental lactogen, and other hormones. The invention specifically encompasses antibodies, antibody fragments, and modifications thereof, as well as polynucleotides, such antisense polynucleotides, interfering RNAs, and small interfering RNAs, and uses thereof, for inhibition of one or more of such hormones. In particular aspects, the invention encompasses methods of producing such inhibitors, compositions comprising one or more of these inhibitors, and methods of inhibiting a cell, e.g., inhibiting cell proliferation, cell survival, or cell motility, especially for a cancer cell, using one or more of the inhibitors. The invention also encompasses methods of diagnosis and monitoring, and methods of treatment, especially for cancer, using one or more of the disclosed compositions or inhibitors.

The invention discloses a probiotic traditional Chinese medicine compound preparation for promoting lactation of sows and improving milk quality. The preparation is compounded by a traditional Chinese medicine compound and probiotics. The traditional Chinese medicine compound is prepared from the following raw materials in parts by weight: 0.5-1.5 parts of angel yeast, 5-15 parts of fructo-oligosaccharide, 1-4 parts of vitamin E, 5-15 parts of cowherb seeds, 1-3 parts of tetrapanax papyriferus, 4-6 parts of a complex enzyme preparation, 1-3 parts of soy isoflavone, 45-50 parts of medical stone powder and 17-25 parts of corn starch. The probiotics are mixed bacterial powder of bacillus subtilis and lactobacillus plantarum. In the probiotic traditional Chinese medicine compound preparation, the viable count of the bacillus subtilis is greater than or equal to 2x10<8>cfu/g and the viable count of the lactobacillus plantarum is greater than or equal to 3x10<8>cfu/g. According to the probiotic traditional Chinese medicine compound preparation, the probiotics and the traditional Chinese medicines are compounded, so that the expression level of prolactin can be improved, the lactation of sows is promoted, the ratio of feed to weight is reduced, and the feed utilization ratio is improved.

The invention discloses a liquid chip kit for detection of a lung cancer. The liquid chip kit comprises coating microspheres, a biotin-labeled detection antibody, streptavidin-phycoerythrin, a reaction buffer solution and a dilution buffer solution, wherein the coating microspheres comprise at least two selected from the group consisting of a microsphere coating a CRP capture antibody, a microsphere coating a Prolactin capture antibody, a microsphere coating a CEA capture antibody, a microsphere coating an NSE capture antibody, a microsphere coating a CK19 capture antibody, a microsphere coating an Axl capture antibody and a microsphere coating an ADAM8 capture antibody, the microspheres coating different capture antibodies have different color codes, and detection antibodies correspond to the capture antibodies. The liquid chip kit provided by the invention has the advantages of high sensitivity and accuracy, rapid detection, good stability and low cost.